Back to Search Start Over

New synthetic opioids: Part of a new addiction landscape

Authors :
Boris Chaumette
Joël Billieux
Laurent Karila
Amine Benyamina
Maude Marillier
Nicolas Franchitto
Neuroimagerie en psychiatrie (U1000)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Sud - Paris 11 (UP11)
Hôpital Purpan [Toulouse]
CHU Toulouse [Toulouse]
Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP)
Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées
Centre de recherche en épidémiologie et santé des populations (CESP)
Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay
Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Hôpital Paul Brousse
Hôpital Lariboisière-Fernand-Widal [APHP]
Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
McGill University = Université McGill [Montréal, Canada]
University of Luxembourg [Luxembourg]
Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
Université Toulouse III - Paul Sabatier (UT3)
Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)
CCSD, Accord Elsevier
Source :
Neuroscience and Biobehavioral Reviews, Neuroscience and Biobehavioral Reviews, Elsevier, 2019, 106, pp.133-140. ⟨10.1016/j.neubiorev.2018.06.010⟩, Neuroscience and Biobehavioral Reviews, 2019, 106, pp.133-140. ⟨10.1016/j.neubiorev.2018.06.010⟩
Publication Year :
2019
Publisher :
HAL CCSD, 2019.

Abstract

International audience; Synthetic opioids (SO) are a major risk for public health across the world. These drugs can be divided into 2 categories, pharmaceutical and non-pharmaceutical fentanyls. A new generation of SO has emerged on the drug market since 2010. North America is currently facing an opioid epidemic of morbi-mortality, caused by over-prescription of opioids, illegally diverted prescribed medicines, the increasing use of heroin and the emergence of SO. Furthermore, this opioid crisis is also seen in Europe. SO are new psychoactive substances characterized by different feature such as easy availability on the Internet, low price, purity, legality, and lack of detection in laboratory tests. They have not been approved or are not recommended for human use. Opioid misuse is associated with somatic and psychiatric complications. For many substances, limited pharmacological information is available, increasing the risk of harmful adverse events. Health actors and the general population need to be clearly informed of the potential risks and consequences of the diffusion and use of SO.

Details

Language :
English
ISSN :
01497634 and 18737528
Database :
OpenAIRE
Journal :
Neuroscience and Biobehavioral Reviews, Neuroscience and Biobehavioral Reviews, Elsevier, 2019, 106, pp.133-140. ⟨10.1016/j.neubiorev.2018.06.010⟩, Neuroscience and Biobehavioral Reviews, 2019, 106, pp.133-140. ⟨10.1016/j.neubiorev.2018.06.010⟩
Accession number :
edsair.doi.dedup.....60441245ec9c456c3796d81bb944a6ca